Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Financing Activities (2022 - 2025)

Entrada Therapeutics has reported Cash from Financing Activities over the past 4 years, most recently at $192000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $192000.0 for Q4 2025, down 86.31% from a year ago — trailing twelve months through Dec 2025 was $887000.0 (down 99.14% YoY), and the annual figure for FY2025 was $887000.0, down 99.14%.
  • Cash from Financing Activities for Q4 2025 was $192000.0 at Entrada Therapeutics, up from $8000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TRDA hit a ceiling of $101.4 million in Q2 2024 and a floor of -$11000.0 in Q3 2024.
  • Median Cash from Financing Activities over the past 4 years was $343500.0 (2025), compared with a mean of $7.8 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 38972.0% in 2023 and later plummeted 102.99% in 2024.
  • Entrada Therapeutics' Cash from Financing Activities stood at $358000.0 in 2022, then soared by 92.74% to $690000.0 in 2023, then skyrocketed by 103.19% to $1.4 million in 2024, then crashed by 86.31% to $192000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $192000.0 (Q4 2025), $8000.0 (Q3 2025), and $337000.0 (Q2 2025) per Business Quant data.